<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247413</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00113297</org_study_id>
    <nct_id>NCT03247413</nct_id>
  </id_info>
  <brief_title>Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation</brief_title>
  <official_title>Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic neck and back pain has become one of the leading causes of disability and loss of&#xD;
      productivity. For many patients with facet or sacroiliac joint mediated pain who have&#xD;
      responded to diagnostic nerve blocks, radiofrequency ablation of the nerves innervating the&#xD;
      joints can provide long term relief. Radiofrequency ablation (RFA) is a relatively safe&#xD;
      procedure with minimal risk of adverse events. However, with any procedure involving damage&#xD;
      to the peripheral nervous system, there is risk of post-procedure neuropathic pain. The&#xD;
      investigators will test the hypothesis that dexamethasone injection delivered at the time of&#xD;
      lesion effectively prevents the development of post-ablation neuritis through a&#xD;
      placebo-controlled, double-blind, randomized trial in patients undergoing cervical, thoracic,&#xD;
      lumbar, and sacroiliac joint radiofrequency denervations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each patient serves as his or her own control. Investigators are recruiting patients who are undergoing bilateral procedures. Each patient will receive dexamethasone at each lesion site post-ablation on one side, and placebo (saline) on the other.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The patient, care providers, and principle investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-ablation neuritis</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Neuritis</condition>
  <condition>Radiofrequency Ablation</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg/ml</intervention_name>
    <description>dexamethasone 4 milligram given post-ablation at each lesion site</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo, normal saline administered post-ablation at each lesion site</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with a diagnosis of either cervical, thoracic, or lumbar facet or sacroiliac&#xD;
             joint pain who have responded to medial branch blocks and are already scheduled for&#xD;
             bilateral radiofrequency ablations&#xD;
&#xD;
          -  age greater than 18 years old&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient not previously scheduled for radiofrequency ablation of the cervical,&#xD;
             thoracic, or lumbar facets, or sacroiliac joints&#xD;
&#xD;
          -  on anticoagulation&#xD;
&#xD;
          -  have a pacemaker&#xD;
&#xD;
          -  age less than 18 years old&#xD;
&#xD;
          -  non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akhil Chhatre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akhil Chhatre, MD</last_name>
    <phone>(410) 614-4030</phone>
    <email>achhatr1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teresa Tang, MD</last_name>
    <phone>(410) 502-2447</phone>
    <email>ttang11@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akhil Chhatre, MD</last_name>
      <phone>410-614-4030</phone>
      <email>achhatr1@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

